Figure S1. Study questionnaire regarding demographics, COVID-19 exposure history, and vaccine attitudes of participants.

Date of enrollment:	
Date of sample collected:	Date arrived in USINDOPACOM

_

A. DEN	A. DEMOGRAPHIC		
Please	Please select only one correct answer by checking on the tick box		
Code	Question	Answer	
A1	DOD ID		
A2	Date of birth		
A3	Gender	1 Male 2 Female	
A4	Ethnicity	□1 Hispanic or Latino □2 Not Hispanic or Latino	
A5	Race	□1 American Indian or Alaska Native □2 Asian	
		□ 3 Black/African American □ 4 Native Hawaiian/Pacific Islander	
		□5 White	
A6	Weight	🗆 🗆 pounds A7 Height 🗌 feet, 🗔 inches	
A8	Service	1 Army 2 Marines 3 Navy	
		4 Air Force 5 Other:	
A9	Rank/grade	□1 E1 – E4 □2 E5 – E6 □3 E7 – E9	
		□4 Warrant □5 01 – 03 □6 04 – 06	
A10	Military specialty:		

	VID-19 VACCINATION	
	e answer all questions	•
B1	Question Which COVID-19 vaccine primary series did you receive? DO NOT COUNT boosters	Answer 1 Pfizer/BioNTech BNT162b2 – 2 doses 2 Moderna mRNA-1273 – 2 doses 3 Novavax NVX-CoV2373 – 2 doses 4 Johnson & Johnson Ad26.COV2.S – 1 dose 5 A combination of the above – please specify brand and dose:
B2	Date of completion of primary series (provide BEST estimate in DDMMMYYYY; please utilize <i>proofs of record</i> such as vaccine cards if available)	
B3	Have you received a COVID-19 booster vaccine (if answer is No, skip to C1)?	□1 Yes □2 No
В4	Name and number of vaccine booster ever received (select all applicable options)	 1 Pfizer/BioNTech – 1 booster dose 2 Pfizer/BioNTech – 2 booster doses 3 Pfizer/BioNTech – 3 booster doses 4 Moderna – 1 booster dose 5 Moderna – 2 booster doses 6 Moderna – 3 booster doses
B5	TOTAL number of booster doses received	
B6	Have you received the new BIVALENT COVID-19 vaccine booster (either Pfizer/BioNTech or Moderna)? (This booster targets both the original SARS-CoV-2 strain and the Omicron B.4/B.5 variants, approved by FDA August 2022)	□1 Yes □2 No
Β7	Type and date of receipt of booster vaccines (for type, select either Monovalent or Bivalent; for date, provide BEST estimate in MMDDYYYY; please utilize <i>proofs of record</i> such as vaccine cards if available)	BOOSTER #1: 1 Monovalent 2 Bivalent 3 Date: BOOSTER #2: 1 Monovalent 2 Bivalent 3 Date: BOOSTER #3: 1 Monovalent 2 Bivalent 3 Date:

C. PRIC	R COVID-19 INFECTION			
Please answer all questions				
Code	Question		Answer	
C1	Have you ever had a positive COVID-19 test (if answer is No, skip	o to	🗌 1 Yes	2 No
	D1)?			
C2	How many separate times have you been infected with COVID-1	9		
	either with or without symptoms? (Positive tests separated by m	nore		
	than 90 days WITH normal state of health in between episodes)			
C3	Which COVID test platform was used for the positive test result(s)	1 Antigen	-based (rapid or
	(select all applicable options)?		home test ki	its) – nose swab
			2 PCR-bas	sed – nose swab
			\Box_3 Antibod	y-based - blood draw
C4	Date(s) of positive COVID-19 test(s) (provide best estimate in DDMMMYYYY)	Episode	e #1 :	
		Episode	# 2 (if applic	able):
		Episode	#3 (if applic	able):
C5	Did you seek medical attention during any COVID-related episodes?	□1 Yes	i □2	No
C6	Did you ever have to miss work due to any COVID-related	🗌 1 Yes	s □2	No
	episodes (if answer is No, skip the next question)?			
C7	How many days did you have to miss work in total?			
C8	Were you ever hospitalized during any COVID-related episodes?	□1 Yes	; □2	No

D. HEALTH RISKS				
Please answer all questions by checking on the tick box				
Code	Question	Answer	Guide	
D1	Do you currently use tobacco products?	□1 Yes □2 No	If No, skip to D2	
D1a	Cigarettes - # Cigarettes per day (average)	$\Box\Box\Box$ (cigarettes)		
	Vaping (e-cigarettes) - # e-cig use sessions	$\Box\Box\Box$ (sessions)		
D1b	per day (assume that 1 session consists of			
	15 puffs OR lasts around 10 minutes)			
D1c	Chewing - # Pouches per day (average)	□□□ (pouches)		
D1d	Dipping - # Cans of snuff per day	per day		
Diu	(average)			
D1e	How long have you been using tobacco	\Box \Box \Box (months)		
DIE	products?			
D2	Have you ever used tobacco products in	□1 Yes □2 No	If No, skip to D3	
	the past?			
D2a	How long did you use tobacco products	$\Box\Box$ (months)		
DZu	for?			
	Which tobacco product(s) did you use?	□1 Cigarettes		
D2b	Check all that apply.	□2 Smokeless tobacco		
DZD		(chewing, dipping)		
		□ ₃ Vaping (e-cigarettes)		
D2c	When did you stop using tobacco			
DZC	product? (DDMMMYYYY)			
D3	Take medicine daily	□1 Yes □2 No		
D3a	What type of medicines/drugs you are			
DSU	taking?			

	TUDES regarding VACCINATION	
	answer all questions	
Code E1	QuestionIf there is a new FDA-approved booster vaccine against the most commonly circulating COVID-19 variant, how likely are you to obtain it if it is not mandated by the DoD?	Answer
		\Box_4 More likely than not \Box_5 Highly likely
E2	If your answer above is "highly unlikely," "not very likely," or "neutral," what are your reasons and/or concerns? Check all that apply.	 1 Adverse side effects from the boosters 2 Anxiety/fear of needles 3 Boosters are not very effective 4 Boosters do not provide additional benefit beyond primary series 5 COVID-19 is no longer a major concern 6 Other (please specify):
E3	Out of the above reasons/concerns, which is MOST important to you?	
E4	If the new booster can be administered orally (via a pill or tablet) or intranasally (via inhalation device, drops, or spray) without using any sharps, how likely are you to obtain it if it not mandated? (Assume this booster is FDA- approved)	 Highly unlikely 2 Not very likely 3 Neutral 4 More likely than not 5 Highly likely
E5	For future DoD-mandate or DoD-recommended vaccines, which route of administration do you prefer? (Assume all vaccines are FDA-approved)	 1 Intramuscular/subcutaneous via needles 2 Oral (pill/tablet) 3 Intranasal (inhaled, drops, spray)
E6	Does the annual influenza (flu) vaccine provide protection against COVID-19?	□1 Yes □2 No

Supplemental Methods

Study Design, Enrollment, and Sampling

Thirty-five milliliters (35 mL) of whole blood were collected from each study participant via venipuncture and processed on site within 4 hours and frozen at -80°C. All samples were shipped to two DoD laboratories (Naval Medical Research Command and Walter Reed Army Institute of Research) in Silver Spring, Maryland within 3 weeks from the first enrollment event.

Quantitative ELISA of Receptor-Binding Domain (RBD) and Spike (S) Protein IgG

Antigens used for ELISA were all from ACRO Biosystems. Trimeric S proteins and RBD from Ancestral (SPN-C52H9), Delta (SPN-C52He), BA.4/5 (SPN-C522e), XBB.1.5 (SPN-C524i), EG.5 (SPN-C524u), and BA.2.86 (SPN-C524y), RBD from Ancestral (SPD-C52H3), Delta (SPD-C52Hh), BA.4/5 (SPD-C522r), XBB.1.5 (SPN-C5242), and BA.2.86 (SPD-C5247) were used. All antigens were diluted in 1x phosphate buffered saline without Ca++ and Mg++ (1xdPBS) and ELISA plates were coated with 1ug/ml (100 ul) of antigens overnight. ELISA was performed as previously described [13]. Plates coated with dPBS were used to assess non-antigen-specific binding. Prior to immunoassay, serum samples were heat-inactivated at 56°C for 1 h. Samples were diluted in dPBS and 100 ul of samples were added to the ELISA plates. For S and RBD, we measured IgA and IgG. For IgA and IgG standard curves, microplates were coated with 1 μ g/ml (0.1 ug/well) goat anti-human IgA (Southern Biotech; Cat: 2050-01) and IgG (Southern Biotech; Cat: 2040-01) in dPBS at 4°C overnight. After washing in 1×dPBS-Tween-20, plates were blocked with 5% skim milk in dPBS at 37°C for 1 h. Purified IgA (Athens Research; Cat#: 16-16-090701), and IgG (Athens Research; Cat#: 16-16-090707) were 2-fold serially diluted with Sample Dilution Buffer as standard curves (ranging from 0.4 ng/ml to 800 ng/ml). All plates were then incubated at 37°C for 2 h.

After washing, the plates were incubated with 1:1,000 diluted goat anti-human IgA-HRP (Southern Biotech; Cat: 2050-05) or IgG-HRP (Southern Biotech; Cat: 2040-05), at 37°C for 1 h. HRP was detected with TMB Microwell Peroxidase substrate (SeraCare; Cat: 5120-0077) and the reactions were stopped by 1N sulfuric acid (H2SO4) solution (Fisher, Cat: SA212-1). Plates were read at OD450nm on plate reader (PerkinElmer EnSpire) within 30 min of stopping. We subtracted responses against the non-specific binding (PBS-coated wells) during data finalization to yield antigen-specific response. SARS-CoV-2-specific IgA, IgM or IgG concentrations (ng/ml) were calculated by sigmoidal standard curves using GraphPad Prism 8 and converted to ng/ml based on the dilution factor.

For RBD IgG, a cutoff of 861 ng/ml (corresponding to 2.94 on the log scale) was used as a "responder" threshold, represented as a dashed line in Figure 1. This value was calculated as an average of two RBD IgG titers (816 ng/ml and 906 ng/ml) previously reported in the literature to correlate with high vaccine efficacy rate and clinically significant host viral neutralizing capacity; thus, they could be considered as surrogate markers of protection [27,28].

Pseudovirus Neutralization Assay

Pseudovirus (PV) was produced using the SARS-CoV-2 Spike (S) gene and the lentivirus derived reporter and packaging plasmids previously described [29], and generously made available through BEI resources (NIAID, NIH). Spike gene sequences were obtained from the GSAID database (www.gsaid.org), codon optimized for human expression with 19 amino acids removed from the C-terminus (GeneArt, ThermoFisher), and cloned into a pcDNA3.1+ expression vector. PV neutralization assays were performed as previously described [30]. Serum was heat inactivated at 56°C for one hour prior and sample serum diluted 1:30 (set as limit of detection) in DMEM containing 10% FBS, followed by three-fold serial dilutions in black, flat bottom 96-well plates (Greiner BIO-ONE). After 48-hour incubation, luciferase activities were measured using Pierce Firefly Luc One-Step Glow Assay Kit, according to the manufacturer's instructions. Luminescence was read using an

EnSpire plate reader (PerkinElmer). Data was analyzed using Prism GraphPad software (Version 8.3.1), using nonlinear regression analysis to calculate ND50. The limit of detection of the assay was 30.

Memory B Cells Frequencies and Responses

Cryopreserved PBMCs from the LINKS study were thawed in warm media containing benzonase, then washed with PBS and stained for viability using the Aqua Live/Dead stain (ThermoFisher) and Fc receptors were blocked using normal mouse IgG (Invitrogen #02-6502). After centrifuging and removal of supernatant, cells were stained with fluorochrome conjugated secondary antibodies specific to subdomains of the S protein of SARS-CoV-2 using fluorochrome conjugated streptavidin tetramers conjugated to the biotinylated RBDs of Wuhan 1 (Acrobiosystems cat# SPD-C82E9-25ug), Delta B.1.617.2 (Acrobiosystems cat# SPD-C82Ed-25ug), Omicron BA.5 (Acrobiosystems cat# SPD-C82Ew-25ug), XBB.1.5 (Acrobiosystems cat# SPD-C82Q3-25ug), BA.2.86 Acrobiosystems cat# SPD-C5247-100ug), EG.5 (Acrobiosystems cat# SPD-C82Q5-200ug), and fulllength Wuhan S1 (SinoBiological cat# 40591-V08H) and S2 (Sinobiologicals cat# 40150-V08B3), together with a cocktail of phenotyping antibodies including CD20 AlexaFluor700 (BD Biosciences cat# 560631), IgD APC-H7 (BD Biosciences cat# 561305), IgM BUV395 (BD Biosciences cat# 563903), CD4 BV510 (BD Biosciences cat# 562970), CD16 BV510 (BD Biosciences cat# 563830), CD10 BV650 (BD Biosciences cat# 563734), IgG BUV495 (BD Biosciences cat#741172), CD14 BV510 (BioLegend cat#301842), CD3 BV510 (BioLegend cat#300448), CD56 BV510 (BioLegend cat#362534), CD8a BV510 (BioLegend cat#301048), CD27 BV605 (BioLegend cat#302830), CD21 FITC (BioLegend cat#354910), CD38 PECv7 (BioLegend cat# 303516), CD19 PEDazzle 594 (BioLegend cat# 302252). SARS-CoV-2 antigen positive B cells were identified amongst plasmablast populations, defined as CD19+, dump channel/viability dye negative, CD10-, CD20- and CD38^{bright,} CD27+, and memory IgG populations defined as CD19+, dump channel negative, CD10-, CD20+, CD27+ CD21-/+. Responders within each SARS-CoV-2 antigen tetramer were identified as individuals with positive frequencies within either the memory IgG or plasmablast gate above that of a negative control (prepandemic COVID-19) donor run on the same assay day with LINKS sample sets to draw gates.

T Cells Frequencies and Responses

PBMCs were thawed and counted for cell viability. Among 167 study subjects, samples from 7 subjects yielded viability <40%, and were excluded from further usage. Samples from the rest of 159 subjects yielded an average viability of 92.6% with a standard deviation (SD) of 18.9 and were used for setting up the AIM assays on the same day.

Assay methods for AIM were described previously [31]. Briefly, PBMCs were cultured in the presence of SARS-CoV-2-specific S peptide pools (1mg/mL) in 96-well U-bottom plates at a concentration of 1ug/ml per 500,000 PBMCs in duplicate wells. The S protein peptide pools used in the study were all from JPT Peptide Technologies GmbH and included Ancestral (Cat#: PM-WCPV-S1), Delta (Cat#:PM-SARS2-SMUT06-1), BA.4/5 (Cat#: PM-SARS-2-SMUT10-1), XBB.1.5 (Cat#: PM-SARS2-SMUT15-1), EG.5 (Cat#: PM-SARS-2-SMTU16-1), and BA.2.86 (Cat#: PM-SARS2_SMUT17-1). The negative control was an equimolar of DMSO. For a positive control, phytohemagglutinin (PHA, Roche,5ug/mL) was used to stimulate cells. We have included a pre-pandemic sample from a dengue-exposed subject and stimulated this sample with the same SARS-CoV-2 peptide pools and a Dengue peptide pool during the setup of each assay. If negative responses to SARS-CoV-2 peptide pools and positive responses to the dengue peptide pool were observed, the assay was accepted.

After antigen stimulation for 15-18 h at 37 °C in 5% CO2, PBMCs were washed and stained for 30 min on ice with a cocktail antibodies: CD4-APC-H7 (clone SK3, BD; Cat# 641398), CD8-PerCP (clone SK1, BD Cat#347314), CD134-PE-Cy7 (clone ACT35, Bio Legend; Cat #:350012), CD137-APC (BD; Cat#: 550890), CD69-BV421 (BD; Cat#562884), CD25-PE (BD; Cat#555432), CXCR5-AlexaFluor-488 (clone RF8B2, BD; Cat # 558112), and a live-dead dye (aqua fluorescent reactive dye for 405nM excitation, Invitrogen; L34966A)

for CD4 and CD8 T cells. After staining, cells were then acquired directly on a FACS CANTO II with 3-lasers (BD) and analyzed with FlowJo software (Tree Star Inc.).

The gating strategy for AIM cells was drawn relative to the negative and positive controls for each donor as shown in Supplementary Figure S2. Lymphocytes were first gated on FCS-A vs SSC-A and dead cells were excluded by gating on Live-dead dye. Single cells were selected by excluding doublets using FSC-A and FSC-H. Next, CD4+ and CD8+ T cells were gated. Activated CD4 T cells were further gated on CD134+CD137+ (CD4 AIM) or CD134+CD25+ (a broader AIM); activated CD8 T cells were gated on CD69+CD137+ AIM markers. The antigen activated CD4 and CD8 cells were presented as % CD134+CD137+/total CD4 cells and %CD137+CD69+/total CD8 cells, respectively.

The percentages of the AIM+ cells in duplicate wells were averaged. The antigen-specific AIM responses were obtained by subtracting the AIM responses in DMSO cultures. The Stimulation Index (SI) was calculated by dividing the % of AIM + cells in peptides-stimulated cultures against the % of AIM+ cells in the DMSO control. To obtain the cut-off for positive response, we used 6 pre-pandemic PBMC samples and stimulated the samples with the same antigens. After subtracting the responses in DMSO, we yielded antigen-stimulated responses from these 6 pre-pandemic subjects. We then obtained the mean and SD from all the responses and calculated the cut-off as mean+1.7 SD [32]. The cut-offs for both CD4 AIM and CD8 AIM were 0.05%. A response was considered positive when the SI was greater than 2 and the value after subtracting DMSO was above the cut-off value.

Reagent	Source	Identifier
Chemicals, proteins, and antigens		
TMB Microwell Peroxidase substrate	SeraCare	Cat# 5120-0077
1N sulfuric acid (H2SO4) solution	Fisher Scientific	Cat# SA212-1
LIVE/DEAD [™] Fixable Aqua Dead Cell Stain Kit	Invitrogen	Cat# L34966
	(Thermo Fisher Scientific)	
Immunoglobulin M (IgM)	Athens Research &	Cat# 16-16-090713-M
	Technology	
Immunoglobulin A (IgA)	Athens Research &	Cat# 16-16-090701
	Technology	
Immunoglobulin G (IgG)	Athens Research &	Cat# 16-16-090707
	Technology	
Mouse IgG	Invitrogen	Cat# 02-6502
Antigens (ELISA)		
Ancestral SARS-CoV-2 S Protein	ACROBiosystems	Cat# SPN-C52H9
Delta (B.1.617.2) SARS-CoV-2 S Protein	ACROBiosystems	Cat# SPN-C52He
Omicron (BA.4/5) SARS-CoV-2 S Protein	ACROBiosystems	Cat# SPN-C522e
Omicron (XBB.1.5) SARS-CoV-2 S Protein	ACROBiosystems	Cat# SPN-C524i
Omicron (EG.5) SARS-CoV-2 S Protein	ACROBiosystems	Cat# SPN-C524u
Omicron (BA.2.86) SARS-CoV-2 S Protein	ACROBiosystems	Cat# SPN-C524y
Ancestral SARS-CoV-2 S Protein RBD	ACROBiosystems	Cat# SPD-C52H3
Delta (B.1.617.2) SARS-CoV-2 S Protein RBD	ACROBiosystems	Cat# SPD-C52Hh
Omicron (BA.4/5) SARS-CoV-2 S Protein RBD	ACROBiosystems	Cat# SPD-C522r
Omicron (XBB.1.5) SARS-CoV-2 S Protein RBD	ACROBiosystems	Cat# SPD-C5242
Omicron (BA.2.86) SARS-CoV-2 S Protein RBD	ACROBiosystems	Cat# SPD-C5247
Omicron (B.1.1.529) SARS-CoV-2 S Protein	ACROBiosystems	Cat# NUN-C52Ht
Nucleocapsid protein	_	
Antigens (Memory B Cells)		
Wuhan 1 SARS-CoV-2 S protein RBD	ACROBiosystems	Cat# SPD-C82E9-25ug
Delta (B.1.617.2) SARS-CoV-2 S protein RBD	ACROBiosystems	Cat# SPD-C82Ed-25ug
Omicron (BA.5) SARS-CoV-2 S protein RBD	ACROBiosystems	Cat# SPD-C82Ew-25ug
Omicron (XBB.1.5) SARS-CoV-2 S protein RBD	ACROBiosystems	Cat# SPD-C82Q3-25ug
Omicron (BA.2.86) SARS-CoV-2 S protein RBD	ACROBiosystems	Cat# SPD-C5247-100ug
Omicron (EG.5) SARS-CoV-2 S protein RBD	ACROBiosystems	Cat# SPD-C82Q5-200ug
Wuhan Spike S1	SinoBiological	Cat# 40591-V08H

Wuhan Spike S2	SinoBiological	Cat# 40150-V08B3
Antigens (T Cells)	Sinchioregreen	
Ancestral SARS-CoV-2 S Protein	JPT Peptide Technologies	Cat# PM-WCPV-S1
Delta (B.1.617.2) SARS-CoV-2 S Protein	JPT Peptide Technologies	Cat# PM-SARS2-SMUT06-1
Omicron (BA.4/5) SARS-CoV-2 S Protein	JPT Peptide Technologies	Cat# PM-SARS-2-SMUT10-1
Omicron (XBB.1.5) SARS-CoV-2 S Protein	JPT Peptide Technologies	Cat# PM-SARS2-SMUT15-1
Omicron (EG.5) SARS-CoV-2 S Protein	JPT Peptide Technologies	Cat# PM-SARS-2-SMTU16-1
Omicron (BA.2.86) SARS-CoV-2 S Protein	JPT Peptide Technologies	Cat# PM-SARS2 SMUT17-1
Antibodies		
Goat anti-human IgM	SouthernBiotech	Cat# 2020-01
Goat anti-human IgA	SouthernBiotech	Cat# 2050-01
Goat anti-human IgG	SouthernBiotech	Cat# 2040-01
Goat anti-human IgM-HRP	SouthernBiotech	Cat# 2020-05
Goat anti-human IgA-HRP	SouthernBiotech	Cat# 2050-05
Goat anti-human IgG-HRP	SouthernBiotech	Cat# 2040-05
Mouse anti-human CD20 Alexa Fluor® 700 (clone	BD Biosciences	Cat# 560631
2H7)		
Mouse anti-human IgD APC-H7 (clone IA6-2)	BD Biosciences	Cat# 561305
Mouse anti-human IgM BUV395 (clone G20-127)	BD Biosciences	Cat# 563903
Mouse anti-human CD4 BV510 (clone SK3)	BD Biosciences	Cat# 562970
Mouse anti-human CD16 BV510 (clone 3G8)	BD Biosciences	Cat# 563830
Mouse anti-human CD10 BV650 (clone HI10a)	BD Biosciences	Cat# 563734
Mouse anti-human IgG BUV496 (clone G18-145)	BD Biosciences	Cat# 741172
Mouse anti-human CD14 BV510 (clone M5E2)	BioLegend	Cat# 301842
Mouse anti-human CD3 BV510 (clone UCHT1)	BioLegend	Cat# 300448
Mouse anti-human CD56 BV510 (clone 5.1H11)	BioLegend	Cat# 362534
Mouse anti-human CD8a BV510 (clone RPA-T8)	BioLegend	Cat# 301048
Mouse anti-human CD27 BV605 (clone O323)	BioLegend	Cat# 302830
Mouse anti-human CD21 FITC (clone Bu32)	BioLegend	Cat# 354910
Mouse anti-human CD38 PE/Cy7 (clone HIT2)	BioLegend	Cat# 303516
Mouse anti-human CD19 PE/Dazzle 594 (clone	BioLegend	Cat# 302252
HIB19)		
Mouse anti-human CD4 APC-H7 (clone SK3)	BD Biosciences	Cat# 641398
Mouse anti-human CD8 PerCP (clone SK1)	BD Biosciences	Cat# 347314
Mouse anti-human CD134 PE/Cy7 (clone ACT35)	BioLegend	Cat# 350012
Mouse anti-human CD137 APC (clone 4B4-1)	BD Biosciences	Cat# 550890
Mouse anti-human CD69 BV421 (clone FN50)	BD Biosciences	Cat# 562884
Mouse anti-human CD25 PE (clone M-A251)	BD Biosciences	Cat# 555432
Rat anti-human CXCR5 Alexa Fluor® 488 (clone	BD Biosciences	Cat# 558112
RF8B2)		